IP Library › Granted Patent US 11,445,710
Granted Patent B2
US 11,445,710 · App. 15/870,621 · Granted Sep 20, 2022

Antibody producing non-human animals

Inventors: Ton Logtenberg (Driebergen, NL); Mark Throsby (Utrecht, NL); Robert A. Kramer (Utrecht, NL); Rui D. Pinto (Utrecht, NL); Cornelis A. De Kruif (De Bilt, NL); Erwin Houtzager (Zeist, NL)
Assignee: Merus N.V.
A01K67/0275A01K67/027A01K67/0278C07K16/00C07K16/462C12N15/8509A01K2207/15A01K2217/052A01K2217/075A01K2217/15A01K2217/206A01K2227/105A01K2267/01C07K14/47C07K16/005C07K16/10C07K16/1282C07K16/22C07K16/248C07K16/2863C07K16/32C07K2317/10C07K2317/14C07K2317/21C07K2317/24C07K2317/31C07K2317/34C07K2317/51C07K2317/515C07K2317/52C07K2317/55C07K2317/56C07K2317/622C07K2317/64C07K2317/76C07K2317/94C07K2319/00C12P21/00G01N33/56966
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,445,710
App. No.
15/870,621
Granted
Sep 20, 2022
Kind
B2
Abstract

Described are transgenic, non-human animals comprising a nucleic acid encoding an immunoglobulin light chain, whereby the immunoglobulin light chain is human, human-like, or humanized. The nucleic acid is provided with a means that renders it resistant to DNA rearrangements and/or somatic hypermutations. In one embodiment, the nucleic acid comprises an expression cassette for the expression of a desired molecule in cells during a certain stage of development in cells developing into mature B cells. Further provided is methods for producing an immunoglobulin from the transgenic, non-human animal.

Claims (11)

1. A transgenic mouse that has been immunized to generate an immune response against an antigen, wherein the genome of said mouse comprises a transgene encoding a rearranged immunoglobulin light chain variable region,

wherein the transgene comprises a single human immunoglobulin light chain V gene segment fused to a single human immunoglobulin light chain J gene segment, wherein the transgene lacks a regulatory element that contributes to somatic hypermutation of the light chain variable region, and wherein said rearranged immunoglobulin light chain variable region is linked to an endogenous immunoglobulin light chain constant region gene segment, and

wherein said transgenic mouse comprises a population of B cells that secrete a repertoire of antibodies that bind said antigen, said repertoire of antibodies comprising the immunoglobulin light chain variable region encoded by said transgene and further comprising a counterpart heavy chain variable region resulting from somatic hypermutation in response to said antigen.

2. The transgenic mouse of claim 1 , wherein said transgene comprises a single human immunoglobulin light chain germline V gene segment fused to a single immunoglobulin light chain germline J gene segment.

3. A transgenic murine animal that has been immunized to generate an immune response against an antigen, wherein the genome of said animal comprises a transgene encoding a rearranged immunoglobulin light chain variable region,

wherein the transgene comprises a single human immunoglobulin light chain V gene segment fused to a single human immunoglobulin light chain J gene segment, wherein the transgene lacks a regulatory element that contributes to somatic hypermutation of the light chain variable region, and wherein the transgene comprises a nucleic acid sequence encoding an immunoglobulin light chain constant region, and

wherein said transgenic animal comprises a population of B cells that secrete a repertoire of antibodies that bind said antigen, said repertoire of antibodies comprising the immunoglobulin light chain variable region encoded by said transgene and further comprising a counterpart heavy chain variable region resulting from somatic hypermutation in response to said antigen.

4. The transgenic animal of claim 3 , that is a mouse.

5. The transgenic animal of claim 3 , wherein the transgene comprises a nucleic acid sequence encoding a murine light chain constant region.

6. The transgenic animal of claim 3 , wherein the transgene comprises a nucleic acid sequence encoding a human light chain constant region.

7. The transgenic animal of claim 3 , wherein said transgene comprises a single human immunoglobulin light chain germline V gene segment fused to a single immunoglobulin light chain germline J gene segment.

Assignments (5)
CHANGE OF NAME Recorded Sep 22, 2026
From: MERUS N.V.
To: MERUS B.V.
Reel/Frame 076100/0852 →
NOTICE OF GRANT OF SECURITY INTEREST IN PATENTS Recorded Jan 30, 2026
From: MERUS B.V.
To: WILMINGTON TRUST, NATIONAL ASSOCIATION
Reel/Frame 074562/0322 →
SECURITY INTEREST Recorded Jan 29, 2026
From: MERUS B.V.
To: MORGAN STANLEY SENIOR FUNDING, INC.
Reel/Frame 074532/0434 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 7, 2018
From: LOGTENBERG, TON; THROSBY, MARK; KRAMER, ROBERT A.; PINTO, RUI DANIEL; DE KRUIF, CORNELIS A.; HOUTZAGER, ERWIN
To: MERUS B.V.
Reel/Frame 045130/0830 →
CHANGE OF NAME Recorded Mar 7, 2018
From: MERUS B.V.
To: MERUS N.V.
Reel/Frame 046264/0149 →
Continuity (4)
Continuation 12589181 · Oct 19, 2009
Continuation 12459285 · Jun 29, 2009
Provisional Application 61133274 · Jun 27, 2008
Related Publication 20180134770A1 · May 17, 2018